Lance Rudolph, MD
Internal Medicine · Albuquerque, NMNPI 1376502997
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 235 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Amgen at 36.3% of the total. Among internal medicine clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $15.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Radius Health, Inc.$790
- AstraZeneca$384
- Novo Nordisk$274
- Pfizer$201
- Ultragenyx Pharmaceutical Inc.$106
- plus $564 from 16 others
Across 225 payments — averaging $4511.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$444K
- Bristol Myers Squibb$241K
- Bayer$75K
- Ironwood Pharmaceuticals, Inc$46K
- E.r. Squibb & Sons, L.L.C.$45K
- Sanofi US Services Inc.$42K
- plus $122K from 9 others
What the payments were for
- Food & beverage$3,644100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 80 | $1,324 |
| Radius Health, Inc. | 51 | $790 |
| AstraZeneca(2 entities) | 25 | $384 |
| Novo Nordisk | 29 | $274 |
| Pfizer | 14 | $201 |
| Ultragenyx Pharmaceutical Inc. | 5 | $106 |
| Lilly USA, LLC | 5 | $102 |
| Corcept Therapeutics | 6 | $82 |
| Ipsen Biopharmaceuticals, Inc | 3 | $68 |
| Johnson & Johnson | 3 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| GSK | 2 | $30 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| AbbVie | 1 | $23 |
| Novartis | 1 | $23 |
| Abbott | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Axonics, Inc. | 1 | $16 |
| Exact Sciences | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Merck | 1 | $13 |
How this compares
$3,644 in reported general payments places this provider in the 95th percentile of 578 internal medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TymlosAbaloparatide | 56 | $158,264 |
| EliquisApixaban | 52 | $45,644 |
| PercocetOxycodone Hcl/Acetaminophen | 12 | $36,160 |
| XareltoRivaroxaban | 28 | $31,382 |
| OzempicSemaglutide | 30 | $28,101 |
| JanuviaSitagliptin Phosphate | 12 | $19,255 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $16,045 |
| MyrbetriqMirabegron | 19 | $12,067 |
| Levothyroxine Sodium | 419 | $6,533 |
| Alendronate Sodium | 491 | $5,022 |
| Gabapentin | 213 | $4,577 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 70 | $2,979 |
| Tamsulosin Hcl | 121 | $2,777 |
| Estradiol | 19 | $2,772 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $2,510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Radius Health, Inc.Tymlos | $790 | $158,26456 claims |
| PfizerEliquis | $201 | $45,64452 claims |
| Johnson & JohnsonXarelto | $62 | $31,38228 claims |
| Novo NordiskOzempic | $274 | $28,10130 claims |
| MerckJanuvia | $13 | $19,25512 claims |
| GSKTrelegy Ellipta | $30 | $16,04522 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $12,06719 claims |
| AbbVieSynthroid | $23 | $2,14830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 578 internal medicine providers in New Mexico.
Other internal medicine in Albuquerque
- Edward LewieckiAlbuquerque$491K
- James AdairAlbuquerque$108K
- Gulshan ParasherAlbuquerque$66K
- Mark WalkerAlbuquerque$24K
- Joao TeixeiraAlbuquerque$18K
- Karla AlmarazAlbuquerque$18K
- David SosaAlbuquerque$11K
- Revati ReddyAlbuquerque$7K
- Ross DavidsonAlbuquerque$7K
- Edmee RodriguezAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.